TABLE 1

Probability of best therapy and SUCRA values for ICS/LABA/LAMA combination therapy, LABA/LAMA combination therapy and single long-acting bronchodilator therapy in chronic obstructive pulmonary disease (COPD) patients

Treatment	Probability of being the best therapy %			Specific SUCRA values			Overall SUCRA
	Risk of AECOPD	Change from baseline in FEV₁	Risk of pneumonia	Risk of AECOPD	Change from baseline in FEV₁	Risk of pneumonia	WA of efficacy/safety
ICS/LABA/LAMA combination	99	100	2	0.99	1.00	0.12	0.56
LABA/LAMA combination	1	0	53	0.39	0.50	0.73	0.59
Single long-acting bronchodilator	0	0	45	0.12	0.00	0.65	0.36

SUCRA: surface under the cumulative ranking curve; ICS: inhaled corticosteroids; LABA: long-acting β₂-agonist; LAMA: long-acting muscarinic receptor antagonist; AECOPD: acute exacerbation of COPD; FEV₁: forced expiratory volume in 1 s; WA: weighted average.